J 2024

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

MUSTO, Pellegrino, Jon SALMANTON-GARCIA, Nicola SGHERZA, Rui BERGANTIM, Francesca FARINA et. al.

Basic information

Original name

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

Authors

MUSTO, Pellegrino, Jon SALMANTON-GARCIA, Nicola SGHERZA, Rui BERGANTIM, Francesca FARINA, Andreas GLENTHOJ, Cengiz Seval GULDANE, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Valentina BONUOMO, Yavuz M BILGIN, van Doesum JAAP, Ozren JAKSIC, Benjamin VISEK, Iker FALCES-ROMERO, Monia MARCHETTI, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Marcio NUCCI, Alberto LOPEZ-GARCIA, Federico ITRI, Caterina BUQUICCHIO, Luisa VERGA, Klara PIUKOVICS, Milan NAVRATIL, Graham P COLLINS, Moraima JIMENEZ, Nicola S FRACCHIOLLA, Jorge LABRADOR, Lucia PREZIOSO, Elena ROSSI, Natasha COLOVIC, Stef MEERS, Austin KULASEKARARAJ, Annarosa CUCCARO, Ola BLENNOW, Toni VALKOVIC, Uluhan SILI, Marie-Pierre LEDOUX, Josip BATINIC, Francesco PASSAMONTI, Marina MACHADO, Rafael F DUARTE, Christian Bjorn POULSEN, Gustavo-Adolfo MENDEZ, Ildefonso ESPIGADO, Fatih DEMIRKAN, Martin CERNAN, Chiara CATTANEO, Verena PETZER, Gabriele MAGLIANO, Carolina GARCIA-VIDAL, Shaimaa EL-ASHWAH, Maria GOMES-DA-SILVA, Antonio VENA, Irati ORMAZABAL-VELEZ, van Praet JENS, Michelina DARGENIO, Cristina DE-RAMON, Del Principe Maria ILARIA, Joyce MARQUES-DE-ALMEIDA, Dominik WOLF, Tomas SZOTKOWSKI, Ales OBR, Goekce Melis COLAK, Anna NORDLANDER, Macarena IZUZQUIZA, Alba CABIRTA, Giovanni Paolo Maria ZAMBROTTA, Raul CORDOBA, Pavel ZAK, Emanuele AMMATUNA, Jiri MAYER, Osman ILHAN, Ramon GARCIA-SANZ, Martina QUATTRONE, Elena ARELLANO, Raquel NUNES-RODRIGUES, Ziad EMARAH, Tommaso Francesco AIELLO, Michaela HANAKOVA, Zdenek RACIL, Martina BAVASTRO, Alessandro LIMONGELLI, Laman RAHIMLI, Francesco MARCHESI, Oliver A CORNELY and Livio PAGANO

Edition

Hematological Oncology, Hoboken, WILEY-BLACKWELL, 2024, 0278-0232

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.300 in 2022

Organization unit

Faculty of Medicine

UT WoS

001119708300001

Keywords in English

COVID-19; hematological malignancy; multiple myeloma; SARS-CoV-2

Tags

Tags

International impact, Reviewed
Změněno: 2/2/2024 08:27, Mgr. Tereza Miškechová

Abstract

V originále

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 x 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.